New Initiatives to Bolster the Drug Supply

In 2021, the Ministry of Health announced a series of initiatives to enhance the stability and affordability of the injectable drug supply nationwide. First, ANVISA accelerated the registration and import approval process for over 300 generic injectable drugs facing shortages. This reduced delays in getting alternative products from foreign suppliers to patients. Second, the government invested in upgrading manufacturing facilities of three major public laboratories to boost domestic production capacity. Significant upgrades to quality control systems were provided.

- Expanding Availability of Critical Care Medicines

One key focus has been increasing the availability of Brazil Injectable Drugs for Hospitals & Ambulatory Settings  surgical settings. Medicines for anesthesiology like propofol, sedatives like midazolam, analgesics like fentanyl and morphine, as well as cardiovascular drugs face frequent stockouts or shortages across Brazil. The new initiatives have already led to a more consistent supply of over 50 such medicines in public and private hospitals. Procurement of largescale imports stabilized prices and prevented rationing in critical units.

- Improving Access in Rural and Underserved Areas

In parallel, strategies are targeting improvements in access to essential medicines in remote and disadvantaged regions. Ambulances, health centers and small clinics often faced the greatest difficulties in obtaining timely injectable deliveries. New distribution networks use a hub-and-spoke model to supply district hospitals and outlying facilities more efficiently. Regional stockpiles have also been created to guarantee continuity of care during periods of scarce resources or weather-related transportation issues. These centralized inventory systems draw from surplus supplies across provinces

Get more insights, On Brazil Injectable Drugs for Hospitals & Ambulatory Settings